LexaGene Life Sciences
About this raise
LexaGene Life Sciences is raising funds on Dealmaker Securities. The company is pioneering the technology that provides timely and automated detection of pathogen and bacterial contaminants. LexaGene Life Sciences’ system, MiQLab, is about 300 times faster than the conventional methods and can tap into both biopharma production and veterinary diagnostics. The system is highly accurate and can give results in two hours compared to the 28 days of older methods. Dr. Jack Regan founded LexaGene Life Sciences in August 2023. The current crowdfunding campaign has a minimum target of $25,750 and a maximum target of $5 million. The campaign proceeds will be used for enhancements to the system, hiring, and marketing.
Investment Overview
Not Funded: $0
Deal Terms
Total Commitments
- Platform
- DealMaker Securities
- Start Date
- 11/01/2023
- Close Date
- 10/31/2024
$25,750
$5,000,000
$1,030
Equity - Common
Early Stage
RegCF
$1.03
Company & Team
Company
- Year Founded
- 2023
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $0
- VC Backed?
- No
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | DealMaker Securities | - | $0 | Equity - Common | Not Funded | RegCF |
